中国迟发性运动障碍的药物治疗和研究现状及国内外差距
The current status of drug therapy and research on tardy movement disorder in China and the differ-ences at home and abroad
李睿 1曾端 1和申 1沈一峰 1李华芳2
作者信息
- 1. 200030 上海交通大学医学院附属精神卫生中心
- 2. 200030 上海交通大学医学院附属精神卫生中心;上海市精神心理疾病临床医学研究中心;上海市重性精神病重点实验室
- 折叠
摘要
迟发性运动障碍(tardive dyskinesia,TD)是一种因长期使用抗精神病药而引发的严重药物不良反应,缺乏有效的治疗方法.国内目前已尝试多种药物治疗TD,部分药物具有一定的疗效.然而,相对国外已经批准新药且疗效确切的治疗现状,我国TD治疗与之有较大差距.新型单胺类囊泡转运体2(vesicular monoamine transporter 2,VMAT2)抑制剂的应用和相关研究是中国TD治疗的趋势和方向之一.
Abstract
Tardive dyskinesia(TD)is a serious adverse drug reaction caused by long-term use of antipsy-chotics,and there has been a lack of effective treatment.TD has been treated with several drugs in China,and some drugs have certain efficacy.However,TD therapy in China is different from foreign countries which have approved new drugs and have definite therapeutic effects.The application and research of novel VMAT2 inhibi-tors is one of the trends and directions of TD therapy in China.
关键词
迟发性运动障碍/药物治疗/戊苯那嗪/氘代丁苯那嗪Key words
tardive dyskinesia/drug therapy/valbenazine/deutetrabenazine引用本文复制引用
基金项目
上海市精神心理疾病临床医学研究中心项目(19MC1911100)
&&(2020-017)
出版年
2024
NETL
NSTL
万方数据